AQR Capital Management
ANIK icon

AQR Capital Management’s Anika Therapeutics ANIK Stock Holding History

AQR Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.95M Buy
272,269
+202,989
+293% +$2.36M ﹤0.01% 1906
2025
Q4 		$666K Buy
69,280
+19,817
+40% +$190K ﹤0.01% 2773
2025
Q3 		$465K Sell
49,463
-1,351
-3% -$12.9K ﹤0.01% 2848
2025
Q2 		$538K Buy
50,814
+38,757
+321% +$489K ﹤0.01% 2582
2025
Q1 		$181K Buy
+12,057
New +$201K ﹤0.01% 2911
2024
Q4 		– Sell
-30,692
Closed -$758K – 2867
2024
Q3 		$758K Sell
30,692
-76,681
-71% -$1.99M ﹤0.01% 1981
2024
Q2 		$2.72M Buy
107,373
+8,072
+8% +$209K ﹤0.01% 1318
2024
Q1 		$2.52M Buy
99,301
+5,150
+5% +$125K ﹤0.01% 1302
2023
Q4 		$2.13M Buy
94,151
+20,597
+28% +$426K ﹤0.01% 1316
2023
Q3 		$1.37M Buy
73,554
+41,479
+129% +$860K ﹤0.01% 1479
2023
Q2 		$833K Buy
32,075
+251
+0.8% +$6.72K ﹤0.01% 1630
2023
Q1 		$914K Sell
31,824
-17
-0.1% -$506 ﹤0.01% 1578
2022
Q4 		$942K Buy
31,841
+7,451
+31% +$212K ﹤0.01% 1584
2022
Q3 		$580K Buy
24,390
+9,685
+66% +$223K ﹤0.01% 1721
2022
Q2 		$328K Buy
+14,705
New +$328K ﹤0.01% 1834
2020
Q4 		– Sell
-53,796
Closed -$1.9M – 2181
2020
Q3 		$1.9M Sell
53,796
-63,996
-54% -$2.31M ﹤0.01% 1138
2020
Q2 		$4.44M Sell
117,792
-3,655
-3% -$120K 0.01% 831
2020
Q1 		$3.51M Buy
121,447
+31,368
+35% +$1.27M 0.01% 891
2019
Q4 		$4.67M Buy
90,079
+54,668
+154% +$3.18M 0.01% 983
2019
Q3 		$1.94M Buy
35,411
+29,398
+489% +$1.51M ﹤0.01% 1288
2019
Q2 		$244K Sell
6,013
-9,869
-62% -$360K ﹤0.01% 1932
2019
Q1 		$480K Buy
15,882
+775
+5% +$26.5K ﹤0.01% 1821
2018
Q4 		$508K Buy
15,107
+177
+1% +$6.39K ﹤0.01% 1769
2018
Q3 		$629K Sell
14,930
-14,193
-49% -$561K ﹤0.01% 1877
2018
Q2 		$932K Sell
29,123
-14,253
-33% -$587K ﹤0.01% 1748
2018
Q1 		$2.16M Buy
43,376
+552
+1% +$31.2K ﹤0.01% 1321
2017
Q4 		$2.31M Sell
42,824
-4,455
-9% -$247K ﹤0.01% 1308
2017
Q3 		$2.74M Sell
47,279
-5,461
-10% -$285K ﹤0.01% 1265
2017
Q2 		$2.6M Sell
52,740
-9,600
-15% -$442K ﹤0.01% 1285
2017
Q1 		$2.71M Sell
62,340
-51,336
-45% -$2.45M ﹤0.01% 1252
2016
Q4 		$5.57M Sell
113,676
-34,675
-23% -$1.6M 0.01% 998
2016
Q3 		$7.1M Buy
148,351
+43,754
+42% +$2.16M 0.01% 872
2016
Q2 		$5.61M Buy
104,597
+48,713
+87% +$2.3M 0.01% 869
2016
Q1 		$2.5M Sell
55,884
-47,453
-46% -$1.92M ﹤0.01% 1138
2015
Q4 		$3.94M Sell
103,337
-17,358
-14% -$664K 0.01% 984
2015
Q3 		$3.84M Sell
120,695
-63,619
-35% -$2.22M 0.01% 890
2015
Q2 		$6.09M Sell
184,314
-17,537
-9% -$625K 0.01% 763
2015
Q1 		$8.31M Sell
201,851
-22,301
-10% -$902K 0.02% 601
2014
Q4 		$9.13M Buy
224,152
+62,529
+39% +$2.44M 0.02% 697
2014
Q3 		$5.92M Buy
161,623
+116,000
+254% +$5.01M 0.02% 761
2014
Q2 		$2.11M Buy
45,623
+3,700
+9% +$165K 0.01% 1265
2014
Q1 		$1.72M Buy
41,923
+32,600
+350% +$1.21M 0.01% 1393
2013
Q4 		$356K Buy
+9,323
New +$288K ﹤0.01% 2228

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

AQR Capital Management's ANIK Position: Q1 2026 in Review

AQR Capital Management increased its Anika Therapeutics (ANIK) stake by 293% in Q1 2026, buying an estimated $2.36M and bringing the position to 272,269 shares worth $3.95M. The position accounts for ﹤0.01% of the portfolio, ranked #1906.

AQR Capital Management first reported a position in ANIK in Q4 2013 and has held it in 43 quarters since. The position peaked at $9.13M in Q4 2014. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.

  • AQR Capital Management held 272,269 shares of Anika Therapeutics worth $3.95M as of Q1 2026.
  • AQR Capital Management bought 202,989 Anika Therapeutics shares in Q1 2026, an estimated $2.36M.
  • Anika Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #1906 holding.
  • AQR Capital Management first reported a position in Anika Therapeutics in Q4 2013 and has held it in 43 quarters since.
  • AQR Capital Management's Anika Therapeutics position peaked at $9.13M in Q4 2014.
  • 130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.